Top

International Journal of Clinical Oncology

Published in:

01-06-2020 | Oral Cancer | Original Article

Down-regulation of miR-200c associates with poor prognosis of oral squamous cell carcinoma

Authors: Jian Song, Nian Zhang, Lideng Cao, Di Xiao, Xingchen Ye, En Luo, Zhuang Zhang

Published in: International Journal of Clinical Oncology | Issue 6/2020

Abstract

Background

MicroRNAs (miRNAs) are considered as promising cancer biomarkers. The aim of the present study is to investigate the prognostic significance of miR-200c in patients with oral squamous cell carcinoma (OSCC).

Materials and methods

Quantitative real-time PCR (qRT-PCR) was used to determine the expression levels of miR-200c in 204 pairs of OSCC and adjacent noncancerous. Correlations between miR-200c expression levels and clinicopathological characteristics were investigated. Survival analysis was performed using the Kaplan–Meier method and log-rank test. Multivariate analysis of the prognostic factors was performed with a Cox proportional hazards regression model.

Results

The expression of miR-200c was significantly down-regulated in OSCC tissues compared with adjacent non-tumor tissues (p < 0.0001). Low expression of miR-200c in tumor tissues was significantly correlated with the positive N classification (p = 0.013), advanced TNM stage (p = 0.007) and poor differentiation grade (p = 0.026). Lower miR-200c expression in patients was significantly associated with poor recurrence-free survival (RFS, p = 0.0003) and overall survival (OS, p = 0.0026). Multivariate analysis confirmed that low miR-200c expression was an independent predictor for poor RFS (hazard ratio (HR) 1.705, 95% CI 1.136–2.56, p = 0.01) and OS (HR 1.669, 95% CI 1.03–2.703, p = 0.037) in patients with OSCC.

Conclusion

Our results suggest that the miR-200c might be a potential prognostic biomarker for OSCC.

Zhao X, Sun S, Zeng X et al (2018) Expression profiles analysis identifies a novel three-mRNA signature to predict overall survival in oral squamous cell carcinoma. Am J Cancer Res 8(3):450–461PubMedPubMedCentral

Markopoulos AK (2012) Current aspects on oral squamous cell carcinoma. Open Dent J 6:126–130CrossRefPubMedPubMedCentral

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed

Singhvi HR, Malik A, Chaturvedi P (2017) The role of chronic mucosal trauma in oral cancer: a review of literature. Indian J Med Paediatr Oncol 38(1):44–50CrossRefPubMedPubMedCentral

Scully C, Bagan J (2009) Oral squamous cell carcinoma overview. Oral Oncol 45(4–5):301–308CrossRefPubMed

Woolgar JA, Hall GL (2009) Determinants of outcome following surgery for oral squamous cell carcinoma. Future Oncol 5(1):51–61CrossRefPubMed

Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215–233CrossRefPubMedPubMedCentral

Macfarlane LA, Murphy PR (2010) MicroRNA: biogenesis, function and role in cancer. Curr Genom 11(7):537–561CrossRef

Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704–714CrossRefPubMedPubMedCentral

10.

Irani S (2016) miRNAs signature in head and neck squamous cell carcinoma metastasis: a literature review. J Dent (Shiraz) 17(2):71–83

11.

Jakob M, Mattes LM, Küffer S et al (2019) MicroRNA expression patterns in oral squamous cell carcinoma: hsa-mir-99b-3p and hsa-mir-100-5p as novel prognostic markers for oral cancer. Head Neck 41(10):3499–3515CrossRefPubMed

12.

Shi J, Bao X, Liu Z et al (2019) Serum miR-626 and miR-5100 are promising prognosis predictors for oral squamous cell carcinoma. Theranostics 9(4):920–931CrossRefPubMedPubMedCentral

13.

Baba O, Hasegawa S, Nagai H et al (2016) MicroRNA-155-5p is associated with oral squamous cell carcinoma metastasis and poor prognosis. J Oral Pathol Med 45(4):248–255CrossRefPubMed

14.

Park SM, Gaur AB, Lengyel E et al (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7):894–907CrossRefPubMedPubMedCentral

15.

Wong CM, Wei L, Au SL et al (2015) MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget 6(15):13658–13670CrossRefPubMedPubMedCentral

16.

Zhang JY, Wang YM, Song LB et al (2016) Prognostic significance of microRNA-200c in various types of cancer: an updated meta-analysis of 34 studies. Mol Clin Oncol 4(6):933–941CrossRefPubMedPubMedCentral

17.

Patel S, Shah K, Mirza S et al (2015) Epigenetic regulators governing cancer stem cells and epithelial-mesenchymal transition in oral squamous cell carcinoma. Curr Stem Cell Res Ther 10(2):140–152CrossRefPubMed

18.

Kawakubo-Yasukochi T, Morioka M, Hazekawa M et al (2018) miR-200c-3p spreads invasive capacity in human oral squamous cell carcinoma microenvironment. Mol Carcinog 57(2):295–302CrossRefPubMed

19.

Xie NN, Liu ZX, Wu C et al (2018) MicroRNA-200c suppresses tumor metastasis in oral squamous carcinoma by inhibiting epithelial-mesenchymal transition. Eur Rev Med Pharmacol Sci 22(11):3415–3422PubMed

20.

Yan Y, Yan F, Huang Q (2018) MiR-200c inhibited the proliferation of oral squamous cell carcinoma cells by targeting Akt pathway and its downstream Glut1. Arch Oral Biol 96:52–57CrossRefPubMed

21.

Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, (2016). CA Cancer J Clin 66(2):115–132CrossRefPubMed

22.

Argiris A, Karamouzis MV, Raben D et al (2008) Head and neck cancer. Lancet 371(9625):1695–1709CrossRefPubMed

23.

Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20(8):460–469CrossRefPubMed

24.

Jamali Z, Asl Aminabadi N, Attaran R et al (2015) MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 51(4):321–331CrossRefPubMed

25.

Arunkumar G, Deva Magendhra Rao AK, Manikandan M et al (2018) Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma. Oncol Lett 15(1):649–657PubMed

26.

Chang CJ, Chao CH, Xia W et al (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13(3):317–323CrossRefPubMedPubMedCentral

27.

Tamura M, Sasaki Y, Kobashi K et al (2015) CRKL oncogene is downregulated by p53 through miR-200s. Cancer Sci 106(8):1033–1040CrossRefPubMedPubMedCentral

28.

Kim H, Yang JM, Ahn SH et al (2018) Potential oncogenic role and prognostic implication of microRNA-155-5p in oral squamous cell carcinoma. Anticancer Res 38(9):5193–5200CrossRefPubMed

29.

Wei D, Wang W, Shen B et al (2019) MicroRNA-199a-5p suppresses migration and invasion in oral squamous cell carcinoma through inhibiting the EMT-related transcription factor SOX4. Int J Mol Med 44(1):185–195PubMedPubMedCentral

30.

Warnakulasuriya S (2020) Oral potentially malignant disorders: a comprehensive review on clinical aspects and management. Oral Oncol 102:104550CrossRefPubMed

31.

Mutlu M, Raza U, Saatci Ö et al (2016) miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. J Mol Med (Berl) 94(6):629–644CrossRef

32.

Armand-Labit V, Pradines A (2017) Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts 8(2):61–81CrossRefPubMed

33.

Jarry J, Schadendorf D, Greenwood C et al (2014) The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 8(4):819–829CrossRefPubMedPubMedCentral

Title: Down-regulation of miR-200c associates with poor prognosis of oral squamous cell carcinoma
Authors: Jian Song
Nian Zhang
Lideng Cao
Di Xiao
Xingchen Ye
En Luo
Zhuang Zhang
Publication date: 01-06-2020
Publisher: Springer Singapore
Keywords: Oral Cancer
Oral Cavity Carcinoma
Published in: International Journal of Clinical Oncology / Issue 6/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01649-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis

Salivary metabolites to detect patients with cancer: a systematic review

SAMD14 promoter methylation is strongly associated with gene expression and poor prognosis in gastric cancer

A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction

Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer

RETRACTED ARTICLE: Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer